Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
NEUROCRINE BIOSCIENCES INC (NBIX)
Sector: Healthcare; Industry: Biotechnology

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. The company was founded in 1992 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-02-10 Lloyd-Smith Malcolm Chief Regulatory Officer Sell 1,700 $119.96 $203,926 Yes
2021-02-08 Gano Kyle Chief Business Development Off Sell 6,370 $115.65 $736,702 Yes
2021-02-08 ABERNETHY MATT Chief Financial Officer Sell 2,910 $116.82 $339,942 Yes
2021-02-08 Bozigian Haig P. Chief Development Officer Sell 4,546 $116.33 $528,857 Yes
2021-02-08 BENEVICH ERIC Chief Commercial Officer Sell 5,079 $116.38 $591,089 Yes
2021-02-08 Cooke Julie Chief Human Resources Officer Sell 1,943 $115.84 $225,076 Yes
2021-02-08 ROBERTS EIRY Chief Medical Officer Sell 2,363 $116.78 $275,944 Yes
2021-02-08 Lloyd-Smith Malcolm Chief Regulatory Officer Sell 4,126 $116.26 $479,668 Yes
2021-02-08 Grigoriadis Dimitri E. Chief Research Officer Sell 3,313 $116.16 $384,822 Yes
2021-02-08 GORMAN KEVIN CHARLES Chief Executive Officer Sell 12,888 $116.26 $1,498,368 Yes
2021-02-09 Lippoldt Darin Chief Legal Officer Sell 40,206 $116.19 $4,671,507 Yes
2021-01-26 LYONS GARY A Director Sell 2,000 $120.02 $240,047 No
2021-01-26 Lloyd-Smith Malcolm Chief Regulatory Officer Sell 18,670 $119.97 $2,239,777 Yes
2021-01-26 BENEVICH ERIC Chief Commercial Officer Sell 5,477 $120.02 $657,371 Yes
2021-01-08 ROBERTS EIRY Chief Medical Officer Sell 2,632 $111.06 $292,297 No
2021-01-08 GORMAN KEVIN CHARLES Chief Executive Officer Sell 308,250 $110.22 $33,973,877 Yes
2020-12-01 ABERNETHY MATT Chief Financial Officer Sell 1,645 $94.66 $155,721 No
2020-11-12 BENEVICH ERIC Chief Commercial Officer Sell 2,257 $90.71 $204,723 No
2020-11-12 ROBERTS EIRY Chief Medical Officer Sell 2,257 $90.74 $204,810 No
2020-11-12 Lloyd-Smith Malcolm Chief Regulatory Officer Sell 2,257 $90.73 $204,776 No
2020-11-12 Lippoldt Darin Chief Legal Officer Sell 2,257 $90.72 $204,755 No
2020-11-12 Grigoriadis Dimitri E. Chief Research Officer Sell 2,257 $90.73 $204,784 No
2020-11-12 GORMAN KEVIN CHARLES Chief Executive Officer Sell 3,390 $90.78 $307,748 No
2020-11-12 Gano Kyle Chief Business Development Off Sell 2,257 $90.73 $204,770 No
2020-11-12 Cooke Julie Chief Human Resources Officer Sell 2,257 $90.73 $204,778 No
2020-11-12 Bozigian Haig P. Chief Development Officer Sell 2,257 $90.74 $204,806 No
2020-11-12 ABERNETHY MATT Chief Financial Officer Sell 2,257 $90.74 $204,810 No
2020-11-02 BENEVICH ERIC Chief Commercial Officer Sell 20,595 $96.53 $1,987,972 Yes
2020-10-02 Cooke Julie Chief Human Resources Officer Sell 987 $95.26 $94,022 No
2020-08-05 ROBERTS EIRY Chief Medical Officer Sell 2,257 $118.84 $268,225 No

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.

Insider Smart

Ovintiv Inc (OVV) - Insiders of OVV have been HEAVILY accumulating shares in March with a sub-$3 cost. And the stock is now $11. An awesome 400% gain can't be missed if you found it was heavily accumulated earlier.